Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

in proprietary sales was primarily attributable to increased sales of SEASONIQUE extended cycle oral contraceptive, Plan B Over-the-Counter/Rx and the ParaGard(R) IUC, which more than offset the expected decrease in sales of our SEASONALE extended-cycle oral contraceptive, which has faced generic competition since September 2006, and decreased sales of Adderall(R) IR.

Alliance and Development Revenue

During the first quarter of 2008, the Company reported alliance and development revenue of $32 million, up from $25 million in the prior year period. The increase reflects higher royalties earned from the Company's agreement with Teva Pharmaceuticals on fexofenadine hydrochloride tablets, the generic version of Allegra(R) tablets, and higher reimbursements under its Shire development agreement, which more than offset lower reimbursements under its Adenovirus agreement with the Department of Defense, as the Company completed Phase III clinical trial for Adenovirus during the quarter.

Other Revenue

Other revenue primarily includes revenue from the Company's non-core operations, including the agrochemicals business and the diagnostic, disinfectants, dialysis and infusions (DDD&I) business. Other revenue totaled $11 million for the first quarter of 2008, compared to $12 million in the prior year period.

Margins

Generic: Margins in the generic segment were 50% for the first quarter of 2008, up from 44% in the prior year period. Last year's margins were negatively impacted by a charge of approximately $32 million related to the step-up of inventory acquired from PLIVA and sold in the period.

Proprietary: Margins in the proprietary segment were 68% for the first quarter of 2008, up from 66% in the prior year period.

Update on R&D Activities

Research and development expenses totaled $64 million for the first quarter of 2008, compared to $62 million in the prior year period.

Generic Products

At March 31
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Metabolomics Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study ... a new experimental technique that is being widely ... Metabolites are small molecules that are present in ...
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/25/2014)... BEIJING , July 25, 2014 Sinovac Biotech ... biopharmaceutical products in China , today announced ... second quarter ended June 30, 2014, after market close on ... conference call prior to the market opening on Friday, August ... at 8:00 p.m. China Standard Time) to review the Company,s ...
(Date:7/24/2014)... July 24, 2014  Now available is a stem ... Rehealth Regenerative Therapies , located in Guadalajara, ... active people a new health option: stem cell ... age, countless patients suffer from joint and muscle injuries ... muscle tears, torn rotator cuff, tennis elbow, and knee ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... at American Society of Pharmacognosy, EMERYVILLE, Calif., ... will present seminal information on a new drug ... 7th Annual Oxford International,Conference on the Science of ... April 12-16, 2008. Scott Baggett, Ph.D., a member ...
... April 14 Codexis, Inc. announced,today that it has ... U.S.,Securities and Exchange Commission ("SEC") relating to the proposed ... of the Codexis,registration statement on Form S-1 can be ... shares being offered and the price,range for the offering ...
... and reduced cost for ... pharmaceutical manufacturers, NEW YORK, ... agreement with Chiral Quest, Inc., a manufacturer and,developer of chiral ... chiral products to the pharmaceutical industry., Effective immediately, Sumitomo ...
Cached Biology Technology:Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 2Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2
(Date:7/24/2014)... use of native animal species for food or commercial ... significant factor in the decline of many species of ... indicates that more than half of the species being ... hornbills., "By surveying not only the meat made available ... inside the forest by hunters and brought to villages ...
(Date:7/24/2014)... has identified two factors that characterize sustainable university ... of highly qualified physics teachers. Specifically, one or ... teacher education in combination with institutional motivation and ... Science, Technology, Engineering and Math (STEM) teacher shortages ... points the way for institutions seeking to increase ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2
... and a half acres of Appalachia have been strip-mined, whole ... and communities devastated. Not exactly a promising place for a ... For his startling and bold proposal to clean-up this ... of Appalachia, John Todd, a research professor in the Rubenstein ...
... drug reverses the brain dysfunction inflicted by a genetic ... of TSC patients also suffer from autism, the findings ... autism. Nature Medicine publishes the findings ... mouse model for TSC, the scientists tested rapamycin, a ...
... the Smithsonian,s National Zoo detected a secondary rise in ... Mei Xiang (may-SHONG) earlier this month. The results from ... believe the hormone rise indicates that it would be ... to a cub or comes to the end of ...
Cached Biology News:Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3Drug reverses mental retardation caused by genetic disorder 2